Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, Kate de Santis, Director, Inv
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:9/18/2014)... -- Just days before the government of Sierra ... spread of Ebola, World Vision will begin a massive delivery ... private donations. McKesson, the largest healthcare services company ... affiliate McKesson Medical-Surgical donated four million pairs of latex gloves ... Sierra Leone,s needs for the next five months* ...
(Date:9/18/2014)... VIEW, Calif. and CHESTERBROOK, Pa. ... (Nasdaq: VVUS ) and Auxilium Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) has approved a supplemental ... is now the only FDA-approved erectile dysfunction (ED) medication indicated ... sexual activity. STENDRA is a prescription medication in ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Industry" and "2014 Market Research Report on Global ... its store. Photo - http://photos.prnewswire.com/prnh/20140917/146748 ... on Global Methyl Methacrylate (MMA) Industry" is a ... China and Global Methyl Methacrylate (MMA) ...
Breaking Medicine Technology:World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 2Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 4Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 5
(Date:9/18/2014)... 18, 2014 It is true ... role when building a successful brand or business ... website, has recently compared plenty of professional web ... ), Arvixe and iPage are the best VPS ... importance of web hosting. All-sized businesses or enterprises ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 Finding ... challenging, leaving many dieters feeling that their weight loss ... is specially trained in the science of fast weight ... results without negative side effects. In fact, a recent ... clients lost an average of 20 pounds during the ...
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Hispanic Physicians Association (HPA) Friends and Family Golf tournament ... , The tournament, which will take place at TopGolf ... student scholarships through three golf challenges, “Top Scramble”, “Top ... Equipment is provided at the event and there will ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... SM9541 MEMS low pressure sensor Series designed ... high accuracy. The unique gage and differential offering ... The 14-Bit resolution and 1% accuracy provide the ... stability per year provides the reliability and long-term ...
(Date:9/18/2014)... CA (September 18, 2014) Cardiovascular disease is the ... plays a major role in accelerating its progression. ... treatment to decrease cholesterol-carrying lipoproteins such as small ... A new study, out today in the ... that rosuvastatin may be more effective among prediabetic ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2Health News:Diet Doc Discloses the Results of a Recent In-House Survey Revealing an Average Loss of 20 Pounds Per Month with Their No Carb Diet Plans 2Health News:Diet Doc Discloses the Results of a Recent In-House Survey Revealing an Average Loss of 20 Pounds Per Month with Their No Carb Diet Plans 3Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:SMI Launches Digital MEMS Low Pressure Sensor 2
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... have had breast cancer, a higher intake of soy may ... study of Chinese women suggests. The same link was ... soy intake, the study authors said. The study, while ...
... is an association between type 2 diabetes mellitus and ... to a new study in Gastroenterology , the ... In 2000, the prevalence of type 2 ... people are projected to have the disease by 2030. ...
... (DOD) has awarded a $5 million grant to The ... Cincinnati to further develop a "lab-on-a-chip" device used for ... of severe brain trauma calls for cutting-edge tools to ... days after an injury. Working through the Feinstein Institute, ...
... PALO ALTO, CA (OCTOBER 15, 2010) Terminal metastatic ... of all cancer deaths has now been effectively treated ... Genomic Systems, citing research published online in the Proceedings ... Research conducted by Robert J. Debs, M.D., senior scientist ...
... 18, 2010 Estimates of the prevalence of liver ... has non‐alcoholic fatty liver disease (NAFLD). NAFLD is now ... in the United States, a trend related to the ... progressive form of NAFLD, can lead to cirrhosis and ...
... 18, 2010 At the American College of ... Antonio, Texas, several studies of the effectiveness of ... diagnostic strategies such as capsule endoscopy (CE) and ... patients with inflammatory bowel disease (IBD) and avoiding ...
Cached Medicine News:Health News:Soy May Reduce Breast Cancer Recurrence: Study 2Health News:Soy May Reduce Breast Cancer Recurrence: Study 3Health News:Type 2 diabetes and insulin use are associated with colorectal cancer in men 2Health News:Feinstein Institute to share $5M US Department of Defense grant 2Health News:Genomic Systems announces 'moratorium on studying and treating terminal cancer has ended' 2Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 2Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 3Health News:Diagnostic techniques help IBD patients avoid ionizing radiation exposure 2Health News:Diagnostic techniques help IBD patients avoid ionizing radiation exposure 3Health News:Diagnostic techniques help IBD patients avoid ionizing radiation exposure 4
For children up to 4 years of age 11 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... The HAAG-STREIT OM 900 Ophthalmometer uses ... the three requirements of Helmholtz: 1. The ... of the distance between the Ophthalmometer and ... are independent of the distance between the ...
Advanced Corneal Topography System with integrated Keratometer. Keratometric and topographic measurements all in one instrument....
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For children up to 4 years of age. 11 mm internal diameter of t...
Medicine Products: